

ORIGINAL RESEARCH

Open Access



Virulence factors in multidrug (MDR) and Pan-drug resistant (XDR) *Pseudomonas aeruginosa*: a cross-sectional study of isolates recovered from ocular infections in a high-incidence setting in southern India

Poonam Naik^{1,2}, Suchita Pandey¹, Satyashree Gagan¹, Sudeshna Biswas¹ and Joveeta Joseph^{1*} 

Abstract

Background: Global concerns have been raised due to upward trend of Multi-drug Resistant (MDR) *Pseudomonas aeruginosa* reports in ocular infections. Our aim was to characterize the virulence determinants of MDR *P. aeruginosa* causing ocular infections.

Methods: *P. aeruginosa* strains were isolated from 46 patients with conjunctivitis (2), endophthalmitis (11) and active keratitis (25) seen at our Institute, between 2016 and 2020. The isolates were identified by Vitek-2 and characterized based on growth kinetics, biofilm formation, motility, pyoverdine and pyocyanin production, phospholipase and catalase activity, urease production along with expression of exotoxins (exo-A, exo-U and exo-S) and correlated to its antibiotic profiles.

Results: Of the 46 *P. aeruginosa* isolates, 23 were MDR and were significantly ($p = 0.03$) associated with older (> 65) patients, along with higher production of pyoverdine (58.3%), pyocyanin (30.4%), phospholipase (91.6%) and protease (62.5%) activity, formed strong biofilms and exo-A (30.4%). No significant relation between motility, urease and catalase production with antibiotic susceptibility was observed. Heatmap and PCoA analysis confirmed this unique virulence profile associated with MDR-PA strains.

Conclusion: Phenotypic characteristics of *P. aeruginosa* might be responsible for increased colonization and antibiotic resistance observed in vivo and understanding these differences may lead to development of clinical guidelines for the management of MDR infections.

Keywords: Endophthalmitis, Multi-drug resistance, *Pseudomonas aeruginosa*, Virulence factors

* Correspondence: joveeta@lvpei.org

¹Jhaveri Microbiology Centre, Brien Holden Eye Research Centre, L. V. Prasad Eye Institute, Hyderabad, India
Full list of author information is available at the end of the article

Introduction

Pseudomonas aeruginosa is the most common Gram-negative isolate causing vision-threatening ocular infections including conjunctivitis, keratitis, orbital cellulitis and endophthalmitis [1–4]. *P. aeruginosa* has low nutritional requirements and can high tolerance to a range of physical conditions, thus making it more pathogenic. *P. aeruginosa* infections are very difficult to eradicate due to their intrinsic resistance to antibiotics [5], in addition, to various virulence factors like flagellin and lipopolysaccharide, as well as secreted products such as cytotoxins [6, 7], elastase [8, 9], alkaline protease [10, 11], protease IV [12], as well as its invasiveness and increased colonization has been reported to contribute to its pathogenicity [13–16]. The presence of these secretion toxin-encoding genes in clinical isolates from different infections is associated with differences in bacterial virulence [17, 18] and clinical outcomes [19]. Proteases is said to contribute to pathogenesis through destruction of connective tissue and degradation of host immunological factors [20] in patients with keratitis. Previous reports have also suggested that pyocyanin and pyoverdine not only contribute to the increased colonization in the lungs of patients with cystic fibrosis, it also interferes with cell respiration, calcium homeostasis and prostacyclin release from lung endothelial cells as well [21]. Another important factor is the ability of *P. aeruginosa* in biofilm formation beginning with the involvement of redundant planktonic cells in a complex and highly regulated physicochemical and biological signalling and thereby confers resistance and protects the bacteria against host immune responses [22–27]. Increasingly, clinical isolates of *Pseudomonas* are exhibiting multiple resistance to antibiotics and becoming pan drug resistant (XDR) [28]. The Emergence of resistant (MDR and XDR) strains in ocular settings, particularly in tropical countries like ours [29], has become a major problem, leaving few alternatives for treatment of these patients [30]. This increase in incidence of MDR and XDR infections is also associated with increased morbidity, mortality, and costs [31, 32]. The aim of our present study was to screen *P. aeruginosa* strains isolated from ocular infections, for their potential to produce various phenotypic virulence factors and correlating them with biofilm formation and their antibiotic susceptibility profile. The hypothesis tested was that MDR and XDR *P. aeruginosa* strains possess distinguishing virulence characteristics in comparison with *P. aeruginosa* that were susceptible to most antibiotics.

Materials and methods

The study was approved by the Institutional Review Board of the L V Prasad Eye Institute, and was performed in accordance with the ethical standards as laid

down in the Declaration of Helsinki. Clinical and microbiology records were retrospectively reviewed for patients who were evaluated at our institute and diagnosed with culture-confirmed infections [keratitis, endophthalmitis, cellulitis, conjunctivitis] due to *P. aeruginosa*.

Bacterial isolates

Forty-six, *Pseudomonas aeruginosa* isolates from various clinical samples from patients with eye infections during the period of April 2016 to March 2020 were included in the study. The preserved isolates were revived and their identification was confirmed by standard microbiological and biochemical methods based on gram staining technique and colonial morphology in addition to Vitek 2 compact system testing using GN strips (bioMérieux).

Antibacterial susceptibility testing

For antibiotic susceptibility testing, minimum inhibitory concentration (MIC) was determined using E-test strips (Himedia) or VITEK® 2 AST cards according to the manufacturer's protocol [33] and this included ciprofloxacin, moxifloxacin, gatifloxacin, ofloxacin, ceftazidime, gentamicin, tetracycline, amikacin, tobramycin, piperacillin, norfloxacin, colistin and imipenem. All results were compared to the Clinical and Laboratory Standards Institute (CLSI) interpretative guidelines and the isolates were classified as susceptible (S), susceptible dose dependent (SDD), and resistant (R) [34]. However, for the purpose of analysis, SDD isolates were clubbed with susceptible isolates (S-PA). Multiple drug resistant (MDR) phenotype was assigned for strains that was resistant to ≥ 3 classes of antibiotics. The *P. aeruginosa* ATCC 27853 strain (American Type Culture Collection), was used as the quality control. The *P. aeruginosa* phenotype was defined as MDR and XDR according to the international expert proposal for interim standards guidelines [18].

Growth curve analysis

The in vitro growth rate was assessed by diluting 1×10^6 CFU/ml of each isolate in BHI broth, on a rotary shaker at 160 rpm for 48 h. At periodic intervals, serial dilution of each culture was plated on an antibiotic-free Mueller Hinton agar and the number of CFUs [colony-forming units] was counted after 24 h incubation at 37 °C.

Phenotypic characterization of *P. aeruginosa* isolates

All phenotypic assays (described below) were performed as three independent biological replicates unless otherwise specified. The *P. aeruginosa* ATCC 27853 strain was used as the positive control to assay motility, biofilm formation and secreted virulence factors.

Measurement of Pyoverdine production and qualitative assessment of pyocyanin

Pyoverdine production by *P. aeruginosa* was assayed spectrophotometrically as previously described [35]. Briefly, the isolates were cultured in MHB to late stationary phase (OD of '3 was recorded at 600 nm). The cultures were then centrifuged at 10,000×g for 2 min and the supernatant were normalized for differences in cell density, and the absorbances measured at 405 nm. The concentration of pyoverdine was then calculated using the extinction coefficient as follows: Molar concentration = Absorbance/Extinction coefficient ($1.9 \times 10^{-4} \text{ M}^{-1} \text{ cm}^{-1}$).

Pyocyanin production was assessed using a qualitative method as described earlier by Alonso et al. [36]. Inoculated plates were incubated at 37 °C for 24 h. Colonies appearing Dark green or blue in colour were considered to be pyocyanin producers.

In vitro microplate biofilm assay

The ability of *P. aeruginosa* strains to develop biofilm was determined on 96-well microtiter plates with crystal violet (CV) staining method as previously described [37]. Briefly, each *P. aeruginosa* strain was cultured on Mueller Hinton agar overnight, and a colony of each isolate was suspended in brain heart infusion (BHI) broth and incubated at 37 °C for 4 h. Bacterial suspensions were then adjusted to an optical density of 0.1 at 600 nm and added to flat-bottomed 96-well sterile culture plates. Following a 48 h incubation period at 37 °C, non-adherent bacteria were removed by washing and stained with 0.1% crystal violet. Following incubation at 30 min, the plates were again washed and ethyl alcohol was added each well, after which the absorbance was measured at 590 nm. The OD₅₉₀ values were then normalized with initial OD₆₀₀ values to account for differences in bacterial growth and biofilm was classified as weak, moderate or strong as described earlier [38].

Motility assay

Motility of the strains was determined in motility medium, which consists 1 (w/v) tryptone, 0.3% yeast extract, 0.5% NaCl and 0.3% agar. Plates were stab-inoculated from overnight cultures and incubated at 37 °C for 24 h. Each strain was assayed in triplicate. The diameter of the circular zone of growth was measured and expressed as a mean value in mm. An isolate showing a change of $\geq 10\%$ was considered highly motile while the rest were categorized as weakly motile or non-motile.

Catalase activity

Determination of the enzyme's presence in the bacterial strains was done using a sterile loop to place a small

amount of growth onto the base of a Petri dish, followed by a drop of hydrogen peroxide and covering the Petri dish with a lid [39]. The development of effervescence indicates a positive result.

Extracellular protease activity

Qualitative protease activity was evaluated by streaking bacteria onto modified basal medium supplemented with 6.2 g/L skim milk protein and incubated for 48 h at 37 °C. Proteolytic activity was demonstrated by a clearing zone (> 12 mm) surrounding the bacterial growth.

Phospholipase [plc] activity assay

Haemolytic activity of the isolates was analysed by presence of clear halos around growth of the organism on blood agar plates after 24 h incubation at 37 °C [40].

Urease test

Urease activity was determined by inoculating the strains on to Christensen's urea agar slope (Oxoid, Thebarton, South Australia) and incubated at 21 °C with protection from light for seven days [41]. Following incubation, the slopes were examined visually for a colour change to pink which was considered to be a positive result, and no change (or a yellow colour) was considered a negative result.

DNA extraction and genotypic detection of virulence genes

Strain DNA was extracted using the QIAamp DNA Mini Kit (50) (QIAGEN) following the manufacturer's instructions. DNA was eluted in 30 μl of elution buffer. The genes, exotoxin S (exoS), exotoxin U (exoU), exotoxinA (exoA) were amplified using the specific primers as described earlier [41, 42]. The PCR protocol involved initial denaturation step at 95 °C for 10 min, followed by 40 cycles of 94 °C for 2 min, annealing (30s at 57 to 65 °C) and 72 °C for 1 min and the final extension step at 72 °C for 5 min.

Statistical analysis

The data were processed on spreadsheets and all statistical analyses were performed using GraphPad prism [5.0]. Phenotypes were treated as either categorical or continuous variables and analysed as appropriate. Wherever applicable all comparisons were evaluated using either χ^2 test or unpaired student t test. The CFU were represented as mean CFU \pm SE of 23 strains in each group at indicated time points and a *P* value of less than 0.05 was considered significant.

Results

Forty-six isolates of *P. aeruginosa* were obtained from various clinical specimens [corneal, conjunctival and

scleral scraping, corneal buttons and vitreous fluids] during the study period and the clinical and demographic details are elaborated in Table 1. Clinical diagnosis included conjunctivitis [3], scleritis [1], endophthalmitis [12], cellulitis [2] and active keratitis [28] diagnosed at our institute, during the study period. Of these isolates, 23 [50%] were found to be MDR which also included 9 (19.5%) XDR strains. As expected, *MDR-PA* was significantly associated with poor visual outcome and prognosis ($p = 0.03$). Interestingly, these MDR strains were significantly ($p = 0.03$) associated with older (> 65) patients. Out of the 23 patients infected with *S-PA* strains, 2 patients underwent evisceration who were diagnosed with post enucleation socket syndrome and microbial keratitis. Additionally, 2 patients with *MDR-PA* caused microbial keratitis and 2 patients with *MDR-PA* induced endophthalmitis cases lead to evisceration.

Growth kinetics differences between MDR-PA and S-PA

To determine potential differences in growth kinetics, the colony forming units on MHA plates were determined for each strain, by plotting the mean CFU of all *S-PA* and *MDR-PA* strains at different time points (0,2,6,18,24 h). At 6 h, 18 h and 24 h significant differences in colony counts were observed between the drug susceptible strains vs multi-drug resistant strains as shown in Fig. 1. The mean CFU at 6 h of *S-PA* Vs *MDR-PA* strains were (7.82×10^7 Vs 1.31×10^9 , $p = 0.01$), at

18 h (5.22×10^9 Vs 5.6×10^{10} , $p = 0.01$) and 24 h (1.01×10^{10} Vs 6.65×10^{10} , $p = 0.03$). The plotted growth curve suggests that *MDR-PA* strains demonstrate significantly higher growth kinetics at later time points compared to *S-PA* strains.

Phenotypic characterization of S-PA and MDR-PA strains

Almost all the strains in both *S-PA* and *MDR-PA* group were catalase positive. While 11/23 (48%) *S-PA* strains were urease positive and 12/23 (52%) of the *MDR-PA* group were positive for urease. Similarly, for citrate production, 91% of *MDR-PA* and 70% of the *S-PA* isolates were positive. Additionally, phospholipase C activity was significantly (chi square test, $p = 0.02$) higher in *MDR-PA* (96%) strains when compared with the *S-PA* strains (70%) as shown in Fig. 2, suggesting a potential role in strain virulence. We found that 7 (30.4%) out of the 23 *MDR-PA* isolates produced pyocyanin while only one *S-PA* (4.3%) isolate produced pyocyanin pigment and there is significant association of pyocyanin production with multidrug resistant ($p = 0.02$).

Looking at the pyoverdine production, the mean absorbance (Fig. 3A) was again significantly higher in *MDR-PA* strains, compared to the *S-PA* (0.39 ± 0.03 nm Vs 0.28 ± 0.02 nm, $p = 0.01$) indicating its role in virulence. Though the *MDR-PA* strains showed increased motility compared to the *S-PA* group, this difference (7.82 ± 0.90 mm vs 8.04 ± 0.04 mm, $p = 0.8$) was not

Table 1 Demographic and microbiological data of the patients included in the study

Categories	Susceptible(<i>S-PA</i>) N = 23(%)	Multi-drug resistant (<i>MDR-PA</i>) N = 23(%)	p-value
Gender			
Male	12 (52.17%)	13 (56.52%)	a1
Female	11 (47.82%)	10 (44.47%)	
Mean Age \pm SD (years)	39.29 \pm 20.05	49.34 \pm 18.67	a0.11
(Range)	(1–80)	(4–73)	
Disease			
Microbial keratitis	14 (60.86)	11 (47.83)	
Endophthalmitis	3 (13.04)	8 (34.78)	
others	6 (26.08)	4 (17.39)	
VA			
> (20/200)	12	16	0.03
> (20/20) - (20/200) <	6	1	
Evisceration	2	4	
Unknown	3	2	
Polymorphs			
(0–1,0–3,0–5)	8	5	0.2
(0–10, plenty)	13	17	
Unknown	2	1	

a: Pearson's chi-squared test




Fig. 1 Clinical isolates of *P. aeruginosa* were plated on MHA at indicated time points. Bacterial load and viability were enumerated by plate count method. Student's test was used for the statistical analysis and data are represented as the mean colony forming units (CFU ± SD) from three sets of independent experiments. **p* < 0.05

statistically significant (Fig. 3B), however, 50% strains belonged to the XDR group. Similarly, protease activity was significantly higher in *MDR-PA* group when compared to *S-PA* group (9.48 ± 0.96 mm vs 5.17 ± 1.88 mm, *p* = 0.02) (Fig. 3C) of which, 80% strains belonged to the XDR phenotype. Analysis of biofilm ability revealed an increased production of biofilm by *MDR-PA* group (39.04 ± 4.88 nm vs 21.10 ± 4.19 nm, *p* = 0.007) as shown

in Fig. 3D. Additionally, among the *S-PA* strains, 48% formed weak biofilms, 4% were moderate, 4% were strong biofilm formers (Fig. 4) and 44% were non biofilm producers. In comparison, in the *MDR-PA* group, 50% of the strains were strong biofilm producer, while 25% were weak biofilm producers. Next, we compared *XDR-PA* and *MDR-PA* group to find out if there is any association of XDR with the virulence traits. In our present





Fig. 2 Graphic representation of frequency of enzymatic virulence factors (catalase, citrate, urease, phospholipase, pyocyanin and exo-A) expression. Pearson's Chi-square test was used for the statistical analysis and data are represented as the mean from three sets of independent experiments. ***p* ≤ 0.01, **p* < 0.05



study we didn't find any significant association of *XDR* with virulence factors (biofilm; $p = 0.51$, urease; $p = 0.13$, protease; $p = 0.42$, motility; $p = 0.40$, pyoverdine; $p = 0.71$, citrate; $p = 0.84$) compared to the *MDR-PA* isolates.

This trend suggests a significant association of biofilm production with multi-drug resistance. Summarizing the virulence factors, we observe that production of catalase,

urease and swarming ability does not have any correlation with the level of antibiotic resistance (Table 2) whereas pyoverdine production, biofilm ability, protease and phospholipase activity were significantly associated with antibiotic resistance and virulence.

Further, we compared association of anatomical site with the virulence factor. Out of the 25 samples 14(56%)




Table 2 Frequency and Statistical correlation of different virulence factors among Resistant and susceptible *P. aeruginosa* strains

Phenotypic character	<i>S-PA</i>	<i>MDR-PA</i>	<i>P</i> -value	OR (95% CI)
Pyoverdine	4	14	^a 0.01*	6.65 (1.7–25.6)
Pyocyanin	1	7	^a 0.02*	0.1 (0.01–0.93)
Biofilm	13	18	^a 0.007*	2.23 (0.6–7.9)
Swarming	4	8	^a 0.12	–
Catalase	23	22	–	–
Protease	5	15	^a 0.02*	3.8 (1.1–12.8)
Phospholipase	16	22	^a 0.01*	5.8 (1.0–31.5)
Urease	11	12	^a 0.88	–

a:Pearson's chi-squared test, *P* probability, *OR* Odds Ratio, *CI* confidence interval

were antibiotic susceptible and 11(44%) were multi-drug resistant. We did not observe any difference in the virulence factor (biofilm; $p = 0.20$, urease; $p = 0.46$, phospholipase; $p = 0.12$, protease; $p = 0.32$, motility; $p = 0.57$, pyoverdine; $p = 0.30$, citrate; $p = 0.4$) between the *S-PA* isolates and *MDR-PA* isolates.

To further confirm our results, we carried out a principal Coordinate Analysis to explore and to visualize dissimilarities of these virulence factors amongst the *S-PA* and *MDR-PA* group. Application of this method to our data showed that the samples could be divided into two principal groups: one consisting primarily of *S-PA* strains (Fig. 5, cluster 1) and second independent clusters of mainly *MDR-PA* strains (Fig. 5, clusters 2). Red dot indicates *MDR-PA* and green indicates *S-PA*. The plot shows the Euclidian distance between the two groups based on how the two groups can be

distinguished. We further constructed a heat map to depict the relative virulence factors expressed by each strain as shown in Fig. 6. The relative colour intensity of heat map gave a good overview of the profile differences between the two groups and demonstrates that the virulence factors are more strongly associated with the *MDR-PA* clinical isolates.

Detection of exotoxins in *S-PA* and *MDR-PA* strains

Our study found that the *exoA* was present in 1/23(4.3%) and *exoS* 2/23(8.69%) of the *S-PA* isolates while we couldn't detect *exoU* gene in any of the *S-PA* isolates. In case of *MDR-PA* isolates, *exoA* was present in 7/23 (30.4%) of the isolates, being significantly associated with multidrug resistance ($p = 0.02$). However, *exo-S* was not detected in any of the *MDR-PA* strains and only 2 strains showed the presence of *exo-U* (8.69%).




Fig. 5 Principal coordinate analysis (PCoA) plot of *S-PA* (left) and *MDR-PA* (right) and the high-resolution display of red square indicates *MDR-PA* isolates while the green dot represents *S-PA* isolates. PCoA plot was generated from the values obtained from Pyoverdine, biofilm, protease and motility test ($n = 23$ in each group)




Fig. 6 Heat map representing virulence factors of ocular clinical isolates of *P. aeruginosa*. The Virulence factors for 46 clinical isolates were tested by different methods specified earlier. Heat map was constructed to compare the *S-PA* and *MDR-PA* isolates. S1-S23 denotes drug susceptible strains, R1-R23 denotes *MDR-PA* strains. Blue represents a lower level of expression and yellow represents a higher level of expression

Discussion

P. aeruginosa is a predominant Gram-negative bacterium causing ocular infections [43]. In the present study, *P. aeruginosa* strains were obtained from corneal ulcers, vitreous fluids and purulent discharge from patients diagnosed at our institute with various infectious conditions. Characterization of the armor of *P. aeruginosa* virulence factors is essential to understand the pathogenesis of this opportunistic pathogen as well as helps in exploring new antimicrobial strategies in MDR strains. *P. aeruginosa* is also known to secrete a number of extracellular products that aid in survival and increased virulence [44]. We hypothesized that distinct virulence traits of ocular *P. aeruginosa* strains would be associated with increased antibiotic resistance in patients with positive *P. aeruginosa* cultures, and as expected we found that 35 out of the 46 *P. aeruginosa* strains had more than two virulence factors. Factor analysis of the measured bacterial variables revealed interrelationships between several of these phenotypes. In our study, the growth curve analysis showed that the *MDR-PA* strains had shorter doubling time, especially at later time points, along with increased swarming motility, and though this association was not statistically significant, it explains its longer persistence in the host. Similarly, pyoverdine which is said to play a critical role in the pathogenesis of host infection by *P. aeruginosa* by removing ferric iron from the host causing mitochondrial damage and compromising ATP production [45] was significantly associated with *MDR-PA* group. This is in agreement with findings by Rodulfo et al. [6] and Finlayson [7] wherein pigment production was reported to be significantly associated with MDR expression along with elastase, protease, siderophore and DNase activity. To date, considerable number of studies have shown the potential importance of pyocyanin in the virulence and pathogenicity of pseudomonal infections [46, 47]. In the present study, ocular *MDR-PA* strains showed a significant association with pyocyanin production.

Our experiments also show that protease production had a role in increased virulence of resistant strains and the XDR group showed higher activity compared to MDR strains. While catalase activity has been demonstrated to be essential for the intracellular survival of bacteria such as *Mycobacterium tuberculosis* [48], our study did not find any association of catalase and urease activity with antibiotic profile. We did however, find a correlation between resistance patterns and phospholipases activity which is reported to play an important role in host cell penetration, cell lysis and are active component of bacterial toxins. On the contrary, other studies have shown association of catalase with virulence. This enzyme has been demonstrated to be an essential factor for the intracellular survival of few bacteria such as *Mycobacterium tuberculosis* [49], *Campylobacter jejuni* [50] and *Helicobacter pylori* [51]. Similarly, Urease activity has been shown to be an important pathogenic factor for the bacteria *Helicobacter pylori* and *Proteus mirabilis* [52–54]. It is also known to be involved in a series of processes that allow bacteria to colonize and induce a strong inflammatory response in the gastric epithelium [55]. Citrate is known important activator of master regulators expression of virulence factors, central metabolism, iron acquisition, and bacterial virulence of *S. aureus* [56].

Biofilm is another reported cause of multi-drug resistance in *P. aeruginosa* [57] and our results were in agreement with previous studies wherein production of biofilm was significantly associated with MDR and XDR strains. An earlier study on *E.coli* strains had suggested that although the virulence of an organism cannot be predicted accurately on the basis of its measurable phenotypes, the presence of multiple virulence factors increases the virulence of the organisms [58], and along with host conditions decrease the need for multiple virulence factors in the strains leading to serious infections [59]. Our study is in agreement with Subedi et al. [45] who reported that virulence factors, extracellular products

including proteases, and the ability to produce biofilm may explain the poor visual prognosis in *P. aeruginosa* endophthalmitis despite rapid antibiotic therapy [60]. The most important extracellular factors of *P. aeruginosa* include exo-S, exo-U, exo-A. Each of the aforementioned factors are known to have toxic effect on mammalian cells [61, 62]. In the present study, we found that exo-A is associated with multidrug resistant not exo-S and exo-U. An earlier study by Wolf et al. [63] has shown that the exoA-deficient mutants exhibit virulence 20 times less than the wild type strain in the mouse models.

Principal component analysis and heat map data reiterates the unique virulence profile of *MDR-PA* strains compared to *S-PA* group and these five factors (pyoverdine production, biofilm ability, protease and phospholipase activity) could thus be used as independent predictors of resistant profiles and virulence. Several limitations however, exist in our study. Firstly, these experiments were measured in vitro of *P. aeruginosa* isolated from primary clinical specimens, although these phenotypes were reproducible upon repeat assay, we only determined potential of expression of virulence factors under defined in vitro conditions, and not actually expressed in the host. Secondly, the visual outcome in resistant strains was not correlated with antibiotic resistance in our clinical practice. Nonetheless, our findings would be more representative of patients with positive cultures for *P. aeruginosa* seen in tertiary eye care hospitals and may aid in clinician decision-making in such a setting.

Conclusion

While antibiotic resistance is multifactorial, recognition of virulent strains by phenotypic characterization, is easier and allows immediate institution of appropriate therapy. To the best of our knowledge, this study was the first investigation regarding the phenotypic virulent characteristics amongst susceptible and resistant strains of *P. aeruginosa* in India. Further studies would focus to understand the genotypic characteristics involved in *MDR-P. aeruginosa* strains, which would aid in developing a rapid signature biomarker for resistant strains.

Acknowledgements

Hyderabad Eye Research Foundation (HERF), Hyderabad.

Financial disclosure

None of the authors have any other financial disclosures.

Authors' contributions

conceptualization, J.J.; methodology, P. N, S. P, S. G, S.B.; software, P. N, S.P; validation, J.J., P.N.; Data analysis, P.N.; data curation, J.J.; writing—original draft preparation, P.N.; writing—review and editing, J.J.; supervision, J.J.; project administration, J.J. All authors read and approved the final manuscript.

Funding

Hyderabad Eye Research Foundation (HERF).

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the Institutional Review Board of the L V Prasad Eye Institute (LEC 09-18-125), and was performed in accordance with the ethical standards as laid down in the Declaration of Helsinki. Clinical and microbiology records were retrospectively reviewed for patients who were evaluated at our institute and diagnosed with culture-confirmed infections [keratitis, endophthalmitis, cellulitis, conjunctivitis] due to *P. aeruginosa*.

Consent for publication

Not applicable.

Competing interests

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Author details

¹Jhaveri Microbiology Centre, Brien Holden Eye Research Centre, L. V. Prasad Eye Institute, Hyderabad, India. ²Research Scholar, Manipal Academy of Higher Education, Manipal, India.

Received: 13 February 2021 Accepted: 22 September 2021

Published online: 28 September 2021

References

- Galvis V, Tello A, Guerra A, Acuña MF, Villarreal D (2014) Antibiotic susceptibility patterns of bacteria isolated from keratitis and intraocular infections at Fundación Oftalmológica de Santander (FOSCAL), Floridablanca. *Colombia Biomedica* 34(0):123–133. <https://doi.org/10.7705/biomedica.v34i0.1636>
- Iwalokun BA, Oluwadun A, Akinsinde KA, Niemogha MT, Nwaokorie FO (2011) Bacteriologic and plasmid analysis of etiologic agents of conjunctivitis in Lagos, Nigeria. *J Ophthalmic Inflamm Infect* 1(3):395–103. <https://doi.org/10.1007/s12348-011-0024-z>
- Choudhury R, Panda S, Sharma S, Sidh V (2012) Staphylococcal Infection, Antibiotic Resistance and Therapeutics. In: Staphylococcal infection, antibiotic resistance and therapeutics, antibiotic resistant bacteria – a continuous challenge in the new millennium. Dr. Marina Pana, editor. IntechOpen Limited, London
- Summaiya M, Sangita R, Neeta K (2012) Ocular infections: rational approach to antibiotic therapy. *Natl J Med Res* 2:122–124
- Lister PD, Wolter DJ, Hanson ND (2009) Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Microbiol Rev* 22:4582–4610 distinct host response. *Virulence*. 2018; 9: 1804–17
- Fleiszig SM, Wiener-Kronish JP, Miyazaki H, Vallas V, Mostov KE, Kanada D, Sawa T, Yen TS, Frank DW (1997) *Pseudomonas aeruginosa*-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. *Infect Immun* 65(2):579–586. <https://doi.org/10.1128/iai.65.2.579-586.1997>
- Feltman H, Schuler G, Khan S, Jain M, Peterson L, Hauser AR (2001) Prevalence of type III secretion genes in clinical and environmental isolates of *Pseudomonas aeruginosa*. *Microbiology (Reading)* 147(10):102659–102669. <https://doi.org/10.1099/00221287-147-10-2659>
- Lau GW, Hassett DJ, Britigan BE (2005) Modulation of lung epithelial functions by *Pseudomonas aeruginosa*. *Trends Microbiol* 13(8):8389–8397. <https://doi.org/10.1016/j.tim.2005.05.011>
- Sadikot RT, Blackwell TS, Christman JW, Prince AS (2005) Pathogen–host interactions in *Pseudomonas aeruginosa* pneumonia. *Am J Respir Crit Care Med* 171(11):111209–111223. <https://doi.org/10.1164/rccm.200408-1044SO>
- Goodman AL, Lory S (2004) Analysis of regulatory networks in *Pseudomonas aeruginosa* by genomewide transcriptional profiling. *Curr Opin Microbiol* 7:139–144
- Tingpej P, Smith L, Rose B, Zhu H, Conibear T, Al Nassafi K, Manos J, Elkins M, Bye P, Willcox M, Bell S, Wainwright C, Harbour C (2007) Phenotypic characterization of clonal and nonclonal *Pseudomonas aeruginosa* strains

- isolated from lungs of adults with cystic fibrosis. *J Clin Microbiol* 45(6): 61697–61704. <https://doi.org/10.1128/JCM.02364-06>
12. Hobden JA (2002) *Pseudomonas aeruginosa* proteases and corneal virulence. *DNA Cell Biol New York: Mary Ann Liebert, Inc* 21:56391–56396
 13. Rodulfo H, Arcia A, Hernández A, Michelli E, Martínez DDV, Guzman M, Sharma A, Donato M (2019) Virulence factors and integrons are associated with MDR and XDR phenotypes in nosocomial strains of *Pseudomonas aeruginosa* in a Venezuelan university hospital. *Rev Inst Med Trop Sao Paulo* 61:e20. <https://doi.org/10.1590/S1678-9946201961020>
 14. Finlayson EA, Brown PD (2011) Comparison of antibiotic resistance and virulence factors in pigmented and non-pigmented *Pseudomonas aeruginosa*. *West Indian Med J* 60:124–132
 15. Minandri F, Imperi F, Frangipani E, Bonchi C, Visaggio D, Facchini M, Pasquali P, Bragonzi A, Visca P (2016) Role of Iron uptake systems in *Pseudomonas aeruginosa* virulence and airway infection. *Infect Immun* 84(8):82324–82335. <https://doi.org/10.1128/IAI.00098-16>
 16. Kang D, Kirienco DR, Webster P, Fisher AL, Kirienco NV (2018) Pyoverdine, a siderophore from *Pseudomonas aeruginosa*, translocates into *C. elegans*, removes iron, and activates a distinct host response. *Virulence* 9(1):804–817
 17. Fleiszig SM, Lee EJ, Wu C, Andika RC, Vallas V, Portoles M, Frank DW (1998) Cytotoxic strains of *Pseudomonas aeruginosa* can damage the intact corneal surface in vitro. *CLAO J* 24:141–147
 18. Hauser AR, Cobb E, Bodi M, Mariscal D, Vallés J, Engel JN et al (2002) Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by *Pseudomonas aeruginosa*. *Crit Care Med* 30(3):3521–3528. <https://doi.org/10.1097/00003246-200203000-00005>
 19. Engel LS, Hill JM, Moreau JM, Green LC, Hobden JA, O'Callaghan RJ (1998) *Pseudomonas aeruginosa* protease IV produces corneal damage and contributes to bacterial virulence. *Invest Ophthalmol Vis Sci* 39:3662–3665
 20. Iglewski BH (1996) *Pseudomonas*. In: Baron S (ed) *Medical Microbiology*, 4th edn. University of Texas Medical Branch. Galveston, Galveston (TX) Chapter 27
 21. Ryder C, Byrd M, Wozniak DJ (2007) Role of polysaccharides in *Pseudomonas aeruginosa* biofilm development. *Curr Opin Microbiol* 10(6): 6644–6648. <https://doi.org/10.1016/j.mib.2007.09.010>
 22. Høiby N, Ciofu O, Johansen HK, Song ZJ, Moser C, Jensen PØ, Molin S, Givskov M, Tolker-Nielsen T, Bjarnsholt T (2011) The clinical impact of bacterial biofilms. *Int J Oral Sci* 3(2):255–265. <https://doi.org/10.4248/IJOS11026>
 23. Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: a common cause of persistent infections. *Science*. 284(5418):54181318–54181322. <https://doi.org/10.1126/science.284.5418.1318>
 24. Hentzer M, Teitzel GM, Balzer GJ, Heydorn A, Molin S, Givskov M, Parsek MR (2001) Alginate overproduction affects *Pseudomonas aeruginosa* biofilm structure and function. *J Bacteriol* 183(18):185395–185401. <https://doi.org/10.1128/JB.183.18.5395-5401.2001>
 25. Matsukawa M, Greenberg EP (2004) Putative exopolysaccharide synthesis genes influence *Pseudomonas aeruginosa* biofilm development. *J Bacteriol* 186(14):144449–144456. <https://doi.org/10.1128/JB.186.14.4449-4456.2004>
 26. Stewart PS, Costerton JW (2001) Antibiotic resistance of bacteria in biofilms. *Lancet*. 358:9276135–9276138
 27. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y (1999) Epidemiology and clinical outcomes of patients with multiresistant *Pseudomonas aeruginosa*. *Clin Infect Dis* 28(5):1128–1133. <https://doi.org/10.1086/514760>
 28. National Nosocomial Infections Surveillance System (2004) National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. *Am J Infect Control* 32(8):8470–8485. <https://doi.org/10.1016/j.ajic.2004.10.001>
 29. Pathengay A, Moreker MR, Puthussera R, Ambatipudi S, Jalali S, Majji AB, Mathai A, Hussain N, Dave V, Sharma S, Das T (2011) Clinical and microbiologic review of culture-proven endophthalmitis caused by multidrug-resistant bacteria in patients seen at a tertiary eye care center in southern India. *Retina*. 31(9):91806–91811. <https://doi.org/10.1097/IAE.0b013e31820f4b9d>
 30. Chatterjee M, Anju CP, Biswas L, Anil Kumar V, Gopi Mohan C, Biswas R (2016) Antibiotic resistance in *Pseudomonas aeruginosa* and alternative therapeutic options. *Int J Med Microbiol* 306(1):148–158. <https://doi.org/10.1016/j.jimm.2015.11.004>
 31. Carmeli Y, Troillet N, Karchmer AW, Samore MH (1999) Health and economic outcomes of antibiotic resistance in *Pseudomonas aeruginosa*. *Arch Intern Med* 159(10):101127–101132. <https://doi.org/10.1001/archinte.159.10.1127>
 32. Fritsche TR, Sader HS, Toleman MA, Walsh TR, Jones RN (2005) Emerging metallo-β-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program. *Clin Infect Dis* 41(s4): 4276–4278. <https://doi.org/10.1086/430790>
 33. Novick WJ (1989) Development of in vitro susceptibility testing criteria and quality control parameters, 2nd ed. *Clin Microbiol Newsl Vol* 11(Issue 8):60–62
 34. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 18(3):3268–3281. <https://doi.org/10.1111/j.1469-0691.2011.03570.x>
 35. Merritt JH, Kadouri DE, O'Toole GA (2005) Growing and analyzing static biofilms. *Curr Protoc Microbiol Chapter 1:Unit 1B.1*. <https://doi.org/10.1002/9780471729259.mc01b01s00>
 36. Alonso B, Fernández-Barat L, Di Domenico EG, Marín M, Cercenado E, Merino I, de Pablos M, Muñoz P, Guembe M (2020) Characterization of the virulence of *Pseudomonas aeruginosa* strains causing ventilator-associated pneumonia. *BMC Infect Dis* 20(1):909
 37. Choy MH, Stapleton F, Willcox MDP, Zhu H (2008) Comparison of virulence factors in *Pseudomonas aeruginosa* strains isolated from contact lens- and non-contact lens-related keratitis. *J Med Microbiol* 57(12):121539–121546. <https://doi.org/10.1099/jmm.0.2008.003723-0>
 38. Oka N, Suzuki T, Ishikawa E, Yamaguchi S, Hayashi N, Gotoh N, Ohashi Y (2015) Relationship of virulence factors and clinical features in keratitis caused by *Pseudomonas aeruginosa*. *Invest Ophthalmol Vis Sci* 56(11): 116892–116898. <https://doi.org/10.1167/iov.15-17556>
 39. Wargo MJ, Ho TC, Gross MJ, Whittaker LA, Hogan DA (2009) GbdR regulates *Pseudomonas aeruginosa* plcH and pchP transcription in response to choline catabolites. *Infect Immun* 77(3):31103–31111. <https://doi.org/10.1128/IAI.01008-08>
 40. Bradbury RS, Reid DW, Inglis TJ, Champion AC (2011) Decreased virulence of cystic fibrosis *Pseudomonas aeruginosa* in *Dictyostelium discoideum*. *Microbiol Immunol* 55(4):4224–4230. <https://doi.org/10.1111/j.1348-0421.2011.00314.x>
 41. Dave A, Samarth A, Karolia R, Sharma S, Karunakaran E, Partridge L, MacNeil S, Monk PN, Garg P, Roy S (2020) Characterization of ocular clinical isolates of *Pseudomonas aeruginosa* from non-contact lens related keratitis patients from South India. *Microorganisms*. 8(2):2260. <https://doi.org/10.3390/microorganisms8020260>
 42. Tanomand A, Farajnia S, Najar Peerayah S, Majidi J (2013) Cloning, expression and characterization of recombinant exotoxin A-flagellin fusion protein as a new vaccine candidate against *Pseudomonas aeruginosa* infections. *Iran Biomed J* 17(1):1–7. <https://doi.org/10.6091/ibj.22.2012>
 43. Teweldemedhin M, Gebreyesus H, Atsbaha AH, Asgedom SW, Saravanan M (2017) Bacterial profile of ocular infections: a systematic review. *BMC Ophthalmol* 17(1):212
 44. Moradali MF, Ghods S, Rehm BH (2017) *Pseudomonas aeruginosa* lifestyle: a paradigm for adaptation, survival, and persistence. *Front Cell Infect Microbiol* 7:39. <https://doi.org/10.3389/fcimb.2017.00039>
 45. Subedi D, Vijay AK, Willcox M (2018) Overview of mechanisms of antibiotic resistance in *Pseudomonas aeruginosa*: an ocular perspective. *Clin Exp Optom* 101(2):2162–2171. <https://doi.org/10.1111/cxo.12621>
 46. Lau GW, Hassett DJ, Ran H, Kong F (2004) The role of pyocyanin in *Pseudomonas aeruginosa* infection. *Trends Mol Med* 10(12):599–606. <https://doi.org/10.1016/j.molmed.2004.10.002>
 47. Lau GW, Ran H, Kong F, Hassett DJ, Mavrodi D (2004) *Pseudomonas aeruginosa* pyocyanin is critical for lung infection in mice. *Infect Immun* 72(7):4275–4278. <https://doi.org/10.1128/IAI.72.7.4275-4278.2004>
 48. Smith I (2003) Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. *Clin Microbiol Rev* 16(3):463–496. <https://doi.org/10.1128/CMR.16.3.463-496.2003>
 49. Manca C, Paul S, Barry CE III, Freedman VH, Kaplan G (1999) *Mycobacterium tuberculosis* catalase and peroxidase activities and resistance to oxidative killing in human monocytes in vitro. *Infect Immun* 67:74–79

50. Day WA Jr, Sajecki JL, Pitts TM, Joens LA (2000) Role of catalase in campylobacter jejuni intracellular survival. *Infect Immun* 68(11):6337–6345. <https://doi.org/10.1128/IAI.68.11.6337-6345.2000>
51. Basu M, Czinn SJ, Blanchard TG (2004) Absence of catalase reduces long-term survival of *Helicobacter pylori* in macrophage phagosomes. *Helicobacter* 9(3):211–216. <https://doi.org/10.1111/j.1083-4389.2004.00226.x>
52. Eaton K, Brooks C, Morgan D, Krakowka S (1991) Essential role of urease in pathogenesis of gastritis induced by *Helicobacter pylori* in gnotobiotic piglets. *Infect Immun* 59(7):2470–2475. <https://doi.org/10.1128/iai.59.7.2470-2475.1991>
53. Jones B, Lockatell CV, Johnson D, Warren J, Mobley HLT (1990) Construction of a urease-negative mutant of *Proteus mirabilis*: analysis of virulence in a mouse model of ascending urinary tract infection. *Infect Immun* 58(4):1120–1123. <https://doi.org/10.1128/iai.58.4.1120-1123.1990>
54. Tsuda M, Karita M, Morsted MG, Okita K, Nakasaki T (1994) A urease-negative mutant of *Helicobacter pylori* constructed by allelic exchange mutagenesis lacks the ability to colonize the nude mouse stomach. *Infect Immun* 62(8):3586–3589. <https://doi.org/10.1128/iai.62.8.3586-3589.1994>
55. Olivera-Severo D, Uberti AF, Marques MS, Pinto MT, Gomez-Lazaro M, Figueiredo C, Leite M, Carlini CR (2017) A New Role for *Helicobacter pylori* Urease: Contributions to Angiogenesis. *Front Microbiol* 8:1883. <https://doi.org/10.3389/fmicb.2017.01883>
56. Ding Y, Liu X, Chen F, di H, Xu B, Zhou L, Deng X, Wu M, Yang CG, Lan L (2014) Metabolic sensor governing bacterial virulence in *Staphylococcus aureus*. *Proc Natl Acad Sci U S A* 111(46):E4981–E4990. <https://doi.org/10.1073/pnas.1411077111>
57. Karami P, Khaledi A, Mashoof RY, Yaghoobi MH, Karami M, Dastan D et al (2020) The correlation between biofilm formation capability and antibiotic resistance pattern in *Pseudomonas aeruginosa*. *Gene Reports* Volume 18: 100561
58. Johnson JR (1991) Virulence factors in *Escherichia coli* urinary tract infection. *Clin Microbiol Rev* 4(1):180–128. <https://doi.org/10.1128/CMR.4.1.80>
59. Raksha R, Srinivasa H, Macaden RS (2003) Occurrence and characterisation of uropathogenic *Escherichia coli* in urinary tract infections. *Indian J Med Microbiol* 21(2):2102–2107. [https://doi.org/10.1016/S0255-0857\(21\)03130-3](https://doi.org/10.1016/S0255-0857(21)03130-3)
60. Abo EA, Negm S, Ismail A, Mostafa AE (2019) An outbreak of post cataract *Pseudomonas aeruginosa* acute endophthalmitis in Egypt. *Bull Natl Res Cent* 43:13
61. Khalifa ABH, Moissenet D, Thien HV, Khedher MA (2011) Virulence factors in *Pseudomonas aeruginosa*: mechanisms and modes of regulation. *Ann Biol Clin* 69(4):393–403
62. de Bentzmann S, Polette M, Zahm J-M, Hinnrasky J, Kileztky C, Bajolet O, Klossek J-M, Filloux A, Lazdunski A, Puchelle E (2000) *Pseudomonas aeruginosa* virulence factors delay airway epithelial wound repair by altering the actin cytoskeleton and inducing overactivation of epithelial matrix metalloproteinase-2. *Lab Invest* 80(2):209–219. <https://doi.org/10.1038/labinvest.3780024>
63. Wolf P, Beile U (2009) *Pseudomonas* exotoxin a: From virulence factor to anti-cancer agent. *Int J Med Microbiol*. 299(3):161–176. <https://doi.org/10.1016/j.ijmm.2008.08.003>

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)